108 related articles for article (PubMed ID: 9831296)
1. Influence of selective VIP receptor agonists in the rat gastric fundus.
Robberecht P; De Neef P; Lefebvre RA
Eur J Pharmacol; 1998 Oct; 359(1):77-80. PubMed ID: 9831296
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
3. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro.
Reed HE; Meyer-Spasche A; Cutler DJ; Coen CW; Piggins HD
Eur J Neurosci; 2001 Feb; 13(4):839-43. PubMed ID: 11207820
[TBL] [Abstract][Full Text] [Related]
5. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
6. Development of high affinity selective VIP1 receptor agonists.
Gourlet P; Vandermeers A; Vertongen P; Rathe J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1539-45. PubMed ID: 9437714
[TBL] [Abstract][Full Text] [Related]
7. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
[TBL] [Abstract][Full Text] [Related]
8. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
[TBL] [Abstract][Full Text] [Related]
9. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
Jiang X; Wang HY; Yu J; Ganea D
Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
[TBL] [Abstract][Full Text] [Related]
11. The P(2)-purinoceptor antagonist suramin is a competitive antagonist at vasoactive intestinal peptide receptors in the rat gastric fundus.
Jenkinson KM; Reid JJ
Br J Pharmacol; 2000 Aug; 130(7):1632-8. PubMed ID: 10928968
[TBL] [Abstract][Full Text] [Related]
12. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
13. Role of VIP1/PACAP receptors in postoperative ileus in rats.
De Winter BY; Robberecht P; Boeckxstaens GE; De Man JG; Moreels TG; Herman AG; Pelckmans PA
Br J Pharmacol; 1998 Jul; 124(6):1181-6. PubMed ID: 9720789
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
15. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors.
Yamada H; Watanabe M; Yada T
Regul Pept; 2004 Dec; 123(1-3):147-53. PubMed ID: 15518905
[TBL] [Abstract][Full Text] [Related]
16. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
[TBL] [Abstract][Full Text] [Related]
17. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
18. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
[TBL] [Abstract][Full Text] [Related]
19. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
20. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis.
Zupan V; Hill JM; Brenneman DE; Gozes I; Fridkin M; Robberecht P; Evrard P; Gressens P
J Neurochem; 1998 May; 70(5):2165-73. PubMed ID: 9572304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
